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ABSTRACT: Two leading European professional societies, the European Society of Human Genetics and the European Society for Human
Reproduction and Embryology, have worked together since 2004 to evaluate the impact of fast research advances at the interface of assisted
reproduction and genetics, including their application into clinical practice. In September 2016, the expert panel met for the third time. The
topics discussed highlighted important issues covering the impacts of expanded carrier screening, direct-to-consumer genetic testing, voiding
of the presumed anonymity of gamete donors by advanced genetic testing, advances in the research of genetic causes underlying male and
female infertility, utilisation of massively-parallel sequencing in preimplantation genetic testing and non-invasive prenatal screening,
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mitochondrial replacement in human oocytes, and additionally, issues related to cross-generational epigenetic inheritance following IVF and
germline genome editing. The resulting paper represents a consensus of both professional societies involved.
Key words: assisted reproductive technology / epigenetics / expanded carrier screening / gamete donor anonymity / germline genome editing /
female infertility / male infertility / mitochondrial replacement therapy / non-invasive prenatal testing / preimplantation genetic testing
Introduction
The two leading European professional societies in the ﬁeld of assisted
reproduction and medical genetics, the European Society of Human
Genetics (ESHG) (ESHG, 2017) and the European Society for Human
Reproduction and Embryology (ESHRE) (ESHRE, 2017), have been work-
ing together since 2004 to evaluate the impact of the rapid progress of
research and diagnostic technologies at the interface of assisted reproduc-
tion and medical/molecular genetics. Previously, the outcomes of the two
consensus meetings have been published (Soini et al., 2006; Harper et al.,
2013) in both society journals. The interdisciplinary expert group (further
referred to in this paper as ‘the panel’) co-opted several new members
and met for the third time in Amsterdam (September 21–22; 2016).
Recently, there have been many research developments in the ﬁeld of
genomics, comprising mainly the ongoing transition from traditional
‘monogenic genetics’ towards comprehensive testing of the human gen-
ome by integrating massively-parallel sequencing (MPS; or synonym
‘next generation sequencing’) approaches, together with advanced bio-
informatics. Currently, it is possible to elucidate the entire single nucleo-
tide-(SNV), copy number-(CNV) and structural (SV) variation of the
human genome, i.e. beyond the original medical indication for which a
patient (together with his or her family) was referred for genetic testing.
These technological advances are being reﬂected in expanded carrier
screening (ECS), voiding of gamete donor anonymity, preimplantation
genetic testing (PGT) and non-invasive prenatal testing (NIPT), and in
our understanding of the underlying causes of male and female infertility.
Likewise, issues related to mitochondrial replacement in human oocytes
and to cross-generational epigenetic inheritance or germline genome
editing (GGE) technologies are gradually creating paradigm shifts in the
ﬁeld of assisted reproductive technology (ART). Therefore, the panel
mainly focused on the aforementioned selected topics, which are cur-
rently being or are likely to be introduced into clinical practice.
Recently, transnational registry data provided evidence that the
number of ART cycles in Europe is gradually increasing (European IVF-
Monitoring Consortium (EIM) for the European Society of Human
Reproduction and Embryology (ESHRE) et al., 2016), with more than
640 000 cycles reported in 2012, making a growing contribution to the
overall birth-rate in many nations in Europe and beyond. The unprece-
dented complexity of generated research data and the fast (and often
hurried) implementation of new technologies into the ﬁelds of assisted
reproduction as well as of reproductive genetics render the translation
of research results into clinical practice challenging. Therefore, due to
the increasing population impact of ART and fast developments in
research, the introduction both of novel diagnostics (Brownstein et al.,
2014) and therapies into routine ART clinical practice requires pru-
dence and evidence (Harper et al., 2017).
It also needs to be acknowledged that there is a blurred boundary
between research and its clinical application. Medical and legal liability
issues may also arise if the roles and responsibilities of different actors
at different stages of translation of research results are not clearly
established. Genetic counselling has become increasingly important for
patients with various disorders associated with infertility and for future
parents to make informed reproductive choices.
The aim of the current consensus paper is to outline the latest develop-
ments in ART and genetics/genomics, including their practical implications
for clinical management of patients with genetic risks and/or infertility.
ECS in preconception- and
gamete donor contexts
An increasing number of preconception carrier tests for autosomal reces-
sive (AR) diseases have become available for couples who want to achieve
a pregnancy. Initially, carrier testing was developed for AR diseases that
were frequent in speciﬁc ethnic groups (e.g. Tay-Sachs disease in Ashkenazi
Jews, hemoglobinopathies in Mediterranean and African populations, and
cystic ﬁbrosis in European-derived populations). Various professional soci-
eties have recommended preconception carrier testing in high-risk popula-
tions (American College of Obsetrics and Gynecology Committee, 2017)
and the American College of Medical Genetics and Genomics 2015
WHATDOES THIS MEAN FOR PATIENTS?
This paper is the report of a meeting of experts from around Europe to assess how the latest developments in genetics might impact on assisted
reproduction.
Their discussion included testing for genetic diseases for people wanting to get pregnant and the growth of commercial genetic testing, which
may mean that anonymity for people who have donated eggs or sperm cannot be guaranteed. They also considered advances in identifying gen-
etic factors in both male and female infertility and in genetic testing or screening of embryos. They discussed early pregnancy screening and tech-
niques involving mitochondria as well as the impact of IVF on the way genes might work and new techniques for editing, or altering, genes.
They concluded that developments in genetics are increasingly relevant in the fertility ﬁeld as some new techniques are already being used in clinics.
They called for international recommendations to consider how new technologies should be introduced into the ﬁeld of assisted reproduction.
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(Edwards et al., 2015; Henneman et al., 2016). Given the technological
advances in the ﬁeld of genetic testing, panels for ECS have become broadly
available, offering parallel analysis of disease-associated variants in multiple
genes, for individuals or couples regardless of their ancestry. A number of
such tests are now provided as commercial products, and even within a
direct-to-consumer (DTC) setting (Borry et al., 2011; Abulí et al., 2016).
The primary objective of ECS in individuals or couples should be to
inform them of possible genetic disease risks for their future offspring and
their reproductive options in order to foster autonomous reproductive
choices (Henneman et al., 2016). Although the secondary outcome of
broadly offered ECS schemes may decrease the frequency of a target condi-
tion, as reported for example in cystic ﬁbrosis (Castellani et al., 2016), its pri-
mary goal is to ensure reproductive autonomy in tested couples. Therefore,
non-directive counselling in a pre-and post-test setting is of utmost import-
ance within this context (Janssens et al., 2017). Still, complex questions may
arise if a ‘positive’ infertile carrier couple would request ART treatment,
while rejecting PGD.Would it, then, be morally acceptable or even morally
obliged for medical professionals to get involved, given their responsibility to
take account the welfare of the possible future child, or to withhold access
to assisted reproduction? (DeWert et al., 2011).
Readily available ECS requires a proper implementation strategy
(Henneman et al., 2016). In this regard, relevant questions need to be
answered ﬁrst, i.e. what are the responsibilities of healthcare profes-
sionals who see couples before pregnancy; which genes and diseases
should be tested for; which population groups should be targeted; who
will pay for ECS; are couples aware that de novo disease-associated var-
iants are not accounted for and that some disease-associated variants
(e.g. CNV, SNV) in multiple AR conditions are not examined due to
the methodology used and its inherent technical limitations?
To ensure successful implementation of population-based ECS, efforts
should be made to increase knowledge about genetic disease (i.e. not
only on AR disorders) within primary care, among gynaecologists, obste-
tricians, and the general public, in order to create appropriate awareness
and address personal beneﬁts of screening in a non-directive manner
(Holtkamp et al., 2017). Such information should include residual risks of
tested diseases and age speciﬁc risks of de novo disease-associated var-
iants (Acuna-Hidalgo et al., 2016). Importantly, dominant de novo muta-
tions represent a non-negligible (1–2%) cause of genetic disorders (Abulí
et al., 2016; Dubov et al., 2016).
The ESHG has recommended that in ECS panels ‘priority should be
given to carrier screening panels that include (a comprehensive set of)
severe childhood-onset disorders (Henneman et al., 2016). Tests should
be designed to achieve high clinical validity (clinical sensitivity, negative and
positive predictive values (PPV) and should have established clinical utility’).
Current and/or future genome-wide approaches to ECS should also strive
to minimise incidental ﬁndings (Howard et al., 2015) since the capacity of
genetic services to provide follow-up counselling is limited (see, for
example, the 2013 overview of clinical genetics stafﬁng in selected
European countries from a survey conducted by ESHG in 2013: ESHG,
2013). Providers should also take into account individual differences in gen-
etic risk and disease severity perception by the general population. Finally,
increasing immigration of non-European populations requires expan-
sion of the disease coverage to those particularly occurring in large
immigrant ethnic groups and may pose interpretational and counsel-
ling challenges both due to a different spectrum of disease-associated
variants (often with unclear phenotypic impact, since there is a gen-
eral lack of evidence in non-European populations because of the
scarceness of respective studies) and to divergent cultural percep-
tions of examined individuals and/or of their families (El-Hazmi,
2004; Boeldt et al., 2015; Holtkamp et al., 2017).
ECS may be of utility for infertile couples when donor gametes are
used to allow the matching of the donor with the respective partner
(Abulí et al., 2016; Dondorp et al., 2014). Couples who already have a
child with a monogenic condition may also be interested in avoiding
other genetic disorders, and consanguineous couples may also beneﬁt
from this approach. Consequently, increased use of ECS may lead to an
increased use of PGD and thus less frequent requirement of prenatal
diagnosis (PND), both leading to a decrease of elective termination of
pregnancy (ETP) for severe genetic disease. Furthermore, antenatal ECS
and genetic testing in different phases of life may become intertwined.
While early offers of preconception ECS may target serious childhood
conditions for which PGD or PND are an option to avoid the live-birth
of an affected child, ECS may also include treatable conditions (e.g.
phenylketonuria or medium-chain acyl-CoA dehydrogenase deﬁciency)
to allow for treatment immediately after birth or even during pregnancy
(e.g. 21-hydroxylase deﬁciency/congenital adrenal hyperplasia)
(Bachelot et al., 2017; Simpson and Rechitsky, 2017).
Finally, there is increasing evidence that combined low-grade somatic
and germline mosaicism eludes current detection techniques and that
routine utilisation of blood leukocytes as a proxy for examination of
germline variation is insufﬁcient. Therefore, if economically and technic-
ally feasible it could be prudent to test in unclear cases genetic variation
in the three major embryonic lineages in a given patient in order to esti-
mate the degree of potential post-zygotic mosaicism (i.e. from white
blood cells reﬂecting mesoderm, urine sediment cells—endoderm, and
dry buccal swab cells—ectoderm). Nonetheless, even after such a
complex genetic testing approach mosaicism cannot be completely
excluded. In this regard low-grade undetected parental mosaicism may
be responsible for erroneously assigned ‘de novo status’ for observed
variation and could skew recurrence-risk counselling (Campbell et al.,
2015). Possible germline mosaicism should thus always be mentioned
and couples should be informed about the empiric <1% recurrence risk
in simplex de novo variants (Campbell et al., 2014).
Thus, ECS may provide a false sense of reassurance, and the lay and
professional public should be duly educated in this regard (Henneman
et al., 2016).
The panel recommends that national professional organizations in the
ﬁeld of ART and medical/clinical genetics either adopt relevant inter-
national guidelines for ECS with modiﬁcation if required, or develop their
own guidelines on how to make ECS responsibly available for their
respective populations. The panel also calls upon ECS providers to trans-
parently declare the inherent limitations of the applied methodology.
Advances in genetic testing and
voiding of anonymity of gamete
donors
Historically, gamete donation has been predominantly anonymous.
Moreover, many heterosexual parents choose not to disclose the
donor origin to their children, regardless of whether the donation was
anonymous or not (Sälevaara et al., 2013; Blake et al., 2014). Most but
not all European countries delegate the decision on whether to dis-
close to the parents (Harper et al., 2016).
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Some registries, such as the Donor Sibling Registry (DSR, 2017),
Donor-Conceived Register (DCR, 2017) and Family Tree DNA
(FTDNA, 2004), allow donors, donor-conceived children and donor sib-
lings to trace each other through genetic ancestry testing, thus possibly
reversing the anonymity of the donor. When both parties have consented
to ﬁnd genetic relatives there is little ethical and legal concern. However,
within the context of DTC genetic testing, the discovery of relatives can
be accidental and/or relatives may be traced without their prior knowl-
edge or consent. In this regard, DTC genetic testing has already been
used by several million people to determine their ancestry (Harper et al.,
2016). The results of these tests, which are usually provided commer-
cially, enable the consumer to match relatives ‘on-line’. This strategy has
also already been broadly used by adoptees and foundlings (Baptista et al.,
2016). Moreover, the current affordable costs of DTC genetic testing
make it accessible to the majority of consumers in Europe, and beyond.
With the growing use of DTC genetic testing, the anonymity of gam-
ete donors can no longer be guaranteed (Harper et al., 2016; Zadeh,
2016). It does not sufﬁce for the donors to refrain from entering gen-
etic data into the databank. If any of their relatives do, the donor’s fam-
ily can be ‘collaterally’ identiﬁed. Also, children whose parents did not
disclose that they were donor-conceived may inadvertently ﬁnd out
about their donor origin. DTC genetic testing may provide interesting
information regarding an individual´s ancestry (although even in this
instance there is a potential for serious misuse of such information;
Abbott, 2012) and sometimes even useful information on genetic pre-
dispositions. Furthermore, donor-conceived children may also ﬁnd
their half-siblings, the donor himself/herself or other relatives through
ancestry testing (Patrinos et al., 2013; Borry et al., 2014).
Consequently, anonymous gamete donors should be informed that
even though the fertility centre or donor agency will strive to protect
their identity, their anonymity cannot be absolutely guaranteed. They
should be made aware of the fact that even if they do not submit their
DNA to one of the donor registries, they themselves or one of their
relatives could be identiﬁed. Also, the donor’s own (future) biological
offspring may ﬁnd half-siblings through these registries. Those donating
or conceiving with donated gametes should keep this possibility in
mind when deciding whether or not to disclose their donor status/
donor conception to their relatives. Another emerging issue is related
to the fact that identity disclosure reopens substantiated analyses and
legal discussions on numerical limits in donor conception regimes in
terms of their potential population genetic impact (Millbank, 2014).
The panel recommends that patients undergoing ART treatment
with gamete donation should be informed that their children may
eventually discover their donor by genetic testing. Furthermore,
laboratories offering DTC genetic testing should transparently inform
their customers about the potential impact of their services on the
possible discovery of non-paternity or unknown family relationships.
ART centres that are using anonymous gamete donors need to pro-
vide clear information that donors may eventually be traced.
Advances in the genetics
of fertility disorders
The ﬁelds of male (MI) and female (FI) infertility have witnessed substantial
research advances on the underlying genetic causes of infertility. However, it
needs to be noted that MI/FI are of complex multifactorial origin and have a
very broad spectrum of clinical manifestations. Moreover, the diagnosis of
‘infertility’ is generally deﬁned in clinical terms only, with little a priori patient
stratiﬁcation involved in scientiﬁc studies. Much of the stated research pro-
gress is mainly due to the utilisation of MPS and other ‘omics’ technologies,
including state-of-the-art bioinformatics approaches. Nonetheless, despite
such advances, current treatment options in MI/FI have not made a sub-
stantial progress (Bieniek and Lo, 2016; Hanson et al., 2017).
Male infertility
The algorithm of genetic testing in MI has not changed. Karyotyping
(mainly aimed at examination of gonosomal aberrations which are the
major cause of MI) is followed by testing of disease-associated variants
in the CFTR gene and/or Y chromosome microdeletions. However, in
~40% of all cases of MI the underlying genetic pathogenesis is
unknown, ‘idiopathic MI’ (Krausz et al., 2015). Genetics might play a
role but there still needs to be progress in the understanding of the
roles of environmental factors, for example obesity or endocrine dis-
ruptors (Ankolkar and Balasinor, 2016), smoking and air pollution
(Bieniek and Lo, 2016) and epigenetic mechanisms (see further).
Another factor which is important to take into account in western
populations is the increasing paternal age and the concurrent increase
of de novo germline disease-associated variants (Girard et al., 2016).
Recently, a 9-year prospective study from a single centre, compris-
ing 1737 cases, has identiﬁed major causes of MI in 40% of all patients
with regards to ‘reduced total spermatozoa counts’ (Punab et al.,
2017). Additional progress was brought by proteomics and expression
proﬁling analyses (Carrell et al., 2016), including the study of relevant
animal models (e.g. Mouse Genome Informatics) (MGI, 2017) and of
the reproductive tract microbiome (Franasiak and Scott, 2015).
However, application of research outcomes into routine clinical prac-
tice has been hampered by unclear deﬁnitions of MI cohorts under
study, including unclear speciﬁcation of ‘idiopathic MI’ (i.e. what exclu-
sion criteria were applied, what exclusion tests were utilised?), which
precludes replication or evidence-based meta-analyses (Hotaling and
Carrell, 2014). Another confounding factor is related to the fact that
many studies use different standards for sperm analyses and do not
always adhere to the standardised World Health Organization criteria
(Hotaling and Carrell, 2014).
The association of SNV variation (Aston, 2014), drawn from
genome-wide association studies (GWAS) in MI, is often based on
small cohorts (Krausz et al., 2015). Nonetheless, there has been
marked progress in the identiﬁcation of disease genes and disease-
associated variants in ‘non-syndromic’ MI. Some of the more promin-
ent instances include teratozoospermia in its rare forms characterised
by globozoospermia with disease-associated variation detected in
DPY19L2 (Ghédir et al., 2016); SPATA16 (ElInati et al., 2016), macro-
zoospermia in AURKC (Ben Khelifa et al., 2012), alterations of sperm
ﬂagella in TUN-STBG1 (Viville et al., 2017; personal communication)
and asthenozoospermia in DNAH1 (Amiri-Yekta et al., 2016),
CATSPER1, GALNTL5 (Takasaki et al., 2014). In the case of spermato-
genic failure characterised by azoospermia and/or oligozoospermia
there has also been progress in terms of identiﬁcation of disease genes
comprising for example TEX11, NR5A1, NR0B1, TEX15 (Okutman
et al., 2015) and MAGEB4, NANOS1, NR5A1, SOHLH1, SYCE1, TAF4B,
WT1 and ZMYND15 (in alphabetical order) (see Table I for gene
names). Interestingly, TEX11 is an X-linked gene with both SNV and
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Table I List of selected genes involved in male and female infertility.
Gene abbreviation Name MIM HGNC GCID Diagnosis
Male infertility
AURKC Aurora Kinase C 603495 11391 GC19P057230 macrozoospermia
CATSPER1 Cation Channel Sperm Associated 1 606389 17116 GC11M066034 asthenozoospermia
CFTR Cystic Fibrosis Transmembrane Conductance Regulator 602421 1884 GC07P117465 obstructive azoospermia
DNAH1 Dynein Axonemal Heavy Chain 1 603332 2940 GC03P052350 asthenozoospermia
DPY19L2 Dpy-19 Like 2 gene 613893 19414 GC12M063558 globozoospermia
GALNTL5 Polypeptide N-Acetylgalactosaminyltransferase-Like 5 615133 21725 GC07P151956 asthenozoospermia
MAGEB4 MAGE Family Member B4 300153 6811 GC0XP030260 azoospermia
NANOS1 Nanos C2HC-Type Zinc-Finger 1 608226 23044 GC10P119029 azoospermia
NR0B1 Nuclear Receptor Subfamily 0 Group B Member 1 300473 7960 GC0XM030322 azoospermia
NR5A1 Nuclear Receptor Subfamily 5 Group A Member 1 184757 7983 GC09M124481 azoospermia
SOHLH1 Spermatogenesis And Oogenesis Speciﬁc Basic Helix-Loop-Helix 1 610224 27845 GC09M135693 azoospermia
SPATA16 Spermatogenesis Associated 16 609856 29935 GC03M172889 globozoospermia
SYCE1 Synaptonemal Complex Central Element Protein 1 611486 28852 GC10M133553 azoospermia
TAF4B TATA-Box Binding Protein Associated Factor 4b 601689 11538 GC18P026225 azoospermia
TEX11 Testis Expressed 11 300311 11733 GC0XM070528 azoospermia
TEX15 Testis Expressed 15, Meiosis And Synapsis Associated 605795 11738 GC08M030808 azoospermia
WT1 Wilms Tumor 1 607102 12796 GC11M032365 azoospermia
ZMYND15 Zinc-Finger MYND-Type Containing 15 614312 20997 GC17P004740 azoospermia
Female infertility
BMP15 Bone Morphogenetic Protein 15 300247 1068 GC0XP050910 primary ovarian insufﬁciency
CLPP Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit 601119 2084 GC19P006369 primary ovarian insufﬁciency
EIF2B2 Eukaryotic Translation Initiation Factor 2B Subunit Beta 606454 3258 GC14P075002 primary ovarian insufﬁciency
FIGLA Folliculogenesis Speciﬁc BHLH Transcription Factor 608697 24669 GC02M070741 primary ovarian insufﬁciency
FMR1 Fragile X Mental Retardation 1 309550 3775 GC0XP147912 primary ovarian insufﬁciency
FOXL2 Forkhead Box L2 605597 1092 GC03M138944 primary ovarian insufﬁciency
FSHR Follicle Stimulating Hormone Receptor 136435 3969 GC02M048866 primary ovarian insufﬁciency
GALT Galactose-1-Phosphate Uridylyltransferase 606999 4135 GC09P034636 primary ovarian insufﬁciency
GFD9 Growth Differentiation Factor 9 601918 4224 GC05M132861 primary ovarian insufﬁciency
HARS2 Histidyl-TRNA Synthetase 2, Mitochondrial 600783 4817 GC05P141975 primary ovarian insufﬁciency
HFM1 HFM1, ATP Dependent DNA Helicase Homolog 615684 20193 GC01M091260 primary ovarian insufﬁciency
HSD17B4 Hydroxysteroid 17-Beta Dehydrogenase 4 601860 5213 GC05P119452 primary ovarian insufﬁciency
LARS2 Leucyl-TRNA Synthetase 2, Mitochondrial 604544 17095 GC03P045405 primary ovarian insufﬁciency
LHCGR Luteinizing Hormone/Choriogonadotropin Receptor 152790 6585 GC02M048647 primary ovarian insufﬁciency
LHX8 LIM Homeobox 8 604425 28838 GC01P075128 primary ovarian insufﬁciency
MCM8 Minichromosome Maintenance 8 Homologous Recombination Repair Factor 608187 16147 GC20P005926 primary ovarian insufﬁciency
MCM9 Minichromosome Maintenance 9 Homologous Recombination Repair Factor 610098 21484 GC06M118813 primary ovarian insufﬁciency
NOBOX NOBOX Oogenesis Homeobox 610934 22448 GC07M144397 primary ovarian insufﬁciency
Continued 5
A
ssisted
reproduction
and
genetics
Downloaded from https://academic.oup.com/hropen/article-abstract/2017/3/hox015/4677351
by guest
on 10 February 2018
CNV hemizygous disease-associated variants, causing female-
transmitted male meiotic arrest (Yatsenko et al., 2015). Although
there is no predominant disease-associated variation observed thus
far, from the clinical point of view identiﬁcation of such variation asso-
ciated with spermatogenic failure could indicate the utility of sperm
cryopreservation at an appropriate age, to preserve fertility in indivi-
duals involved. Novel targeted biomarker assays are under develop-
ment (Bieniek and Lo, 2016), which could improve genetic counselling
and patient stratiﬁcation for targeted ART treatment.
Awareness of rare genetic syndromes is also relevant in unexplained
MI. Although such syndromes are often detected by a medical and
family history, typical dysmorphic features, associated disabilities and
medical examination, i.e. prior to the diagnosis of MI itself, there could
be mild forms of these diseases presenting in adulthood as MI, due to
improved standard medical and social care. These clinical entities, for
example, comprise hypo-gonadotrophic hypogonadism (Kallmann
syndrome—MIM: 308700), where MPS led to the identiﬁcation of add-
itional candidate genes (Quaynor et al., 2016). Research progress has
been made in the case of Klinefelter syndrome by application of testis
transcriptomic analysis (D’Aurora et al., 2015) MI is also commonly
associated with rare syndromes with maldescended testes where
most of the progress in research is again due to the application of
MPS and bioinformatics: Noonan—MIM:163950 (Pevec et al.,
2016), Cleidocranial dysplasia—MIM:119600 (Guo et al., 2015),
Bloom- MIM:210900 (Liu and Huang, 2016) and Silver-Russel syn-
dromes - MIM:180860 (Giabicani et al., 2016). Likewise, primary ciliary
dyskinesia (MIM: 244400) and myotonic dystrophy 1 (MIM:
160900), which are associated in their milder forms with MI, have
been subjected to similar research strategies (Marshall et al., 2015;
Santoro et al., 2016).
The panel recommends that standardised clinical terminology and
inclusion/exclusion criteria for MI should be used to allow replication
studies and evidenced-based meta-analyses to move the ﬁeld forward.
Due to rapid progress in research, selected gene panels may soon
become a useful tool allowing identiﬁcation of additional causes of MI,
and thus improve genetic- and reproductive counselling, facilitate patient
stratiﬁcation and therefore enable more precise ART approaches.
Female infertility
In the same way as in MI, research on the underlying genetic causes of
FI is quickly advancing. Nonetheless, relatively little is still known about
the genetic background of most cases of FI or female subfertility (FSF),
and even less is translated into novel clinical practice. Evidently, FI is of
complex multifactorial origin as reﬂected by the clinical and genetic
heterogeneity of the cohorts under study, which then hinders replic-
ability of previously performed analyses. Presumably hundreds of
genes have to interact in a precise manner during sex determination,
gametogenesis, complex hormone actions/interactions, and embryo
implantation and its early development, in order to create a healthy
offspring. Thus, disorders related to FI/FSF are expected to be highly
polygenic (Laissue, 2015). Considering that in mice more than 500
genes have already been associated with FI (MGI, see above) many
more disease genes are waiting to be identiﬁed in humans in the com-
ing years. Non-coding RNA’s and epigenetic modiﬁcations have also
been implicated in the control of ovarian function and thus their distur-
bances are likely to be associated with FI (Pelosi et al., 2015).
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Chromosomal aberrations remain a major known cause of premature
ovarian insufﬁciency (POI) and recurrent miscarriages, thus decreasing
the chance of successful pregnancy (Yatsenko and Rajkovic, 2014;
Tucker et al., 2016). A sizeable proportion of disorders of sexual devel-
opment are also caused by gonosomal aberrations, and for other aetiolo-
gies, such as hypothalamic-pituitary-gonadal deﬁciencies, many additional
disease-causing genes have already been identiﬁed (Liebaers et al. 2014).
There has been some progress in understanding of the role of gen-
etic disease-causing genes in common multifactorial disorders such as
polycystic ovary syndrome (PCOS) and endometriosis, each affecting
around 10% of women with FI/FSF. In PCOS, better patient stratiﬁca-
tion and functional genomics could provide novel research avenues
(McAllister et al., 2015; Pau et al., 2017), while in endometriosis
(Yotova et al., 2017) abnormal epigenetic mechanisms in stromal cells
may play a pathogenic role.
Progress has also been achieved in the identiﬁcation of monogenic
causes of FI/FSF, in particular for ‘non-syndromic’ POI for which multiple
X-linked and autosomal genes have been identiﬁed as recently reviewed
(Rossetti et al., 2017). POI is highly clinically heterogeneous and is asso-
ciated either with ovarian dysgenesis reﬂected by primary amenorrhea,
or with secondary amenorrhea. However, the majority of POI cases are
‘idiopathic’. Additional disease-causing genes have been identiﬁed by can-
didate gene approaches, GWAS and/or whole exome analyses utilising
MPS. However, disease-associated variants in these genes were reported
in a rather small number of cases, some being conﬁned to speciﬁc popu-
lations (Laissue, 2015; Pelosi et al., 2015; Qin et al., 2015). Interestingly,
recent studies revealed a complex genetic architecture of POI (Bouilly
et al., 2016). The authors screened both known and potential candidate
genes in a clinically well characterised cohort of patients. Disease-
associated variants were found, for example, in BMP15, FIGLA, FOXL2,
GALT, GDF9, LHX8, NOBOX, SMC1β, REC8 and SOHLH1 (in alphabetical
order), which fall into transcription factor TGF-β ligand, enzyme and ‘mei-
osis’ functional categories (Ben Khelifa et al., 2012). In the latter category,
other authors have reported disease-associated variants in STAG3
(Caburet et al., 2014), SYCE1 (de Vries et al., 2014), HFM1 (Wang et al.,
2014), MCM8 and MCM9 (Desai et al., 2017) (Table I for gene names).
From the clinical point of view, variation linked to POI may also predict
the risk of a premature menopause in affected families (Laven, 2015;
Pelosi et al., 2015).
The list of disease-causing genes related to ‘syndromic’ POI, where its
pathogenesis is related to other clinical entities, was reviewed elsewhere
(Qin et al., 2015). In many instances, these multi-system syndromes
rather than FI itself lead to the clinical diagnosis and referral for genetic
testing, often in the pre-reproductive age. Disease-associated variants in
the FOXL2 gene provide an example. Altered function of this gene causes
the blepharophimosis/ptosis/epicanthus inversus syndrome (BPES; MIM:
110100) with or without POI. Progressive external ophthalmoplegia
(MIM: 157640) together with other symptoms, including POI, is caused
by disease-associated variants in POLG thereby implicating mitochondria-
related pathology (Demain et al., 2017a). Disease-associated variants in
GALT (MIM: 230400 for galactosaemia), PMM2 (MIM: 212065 for con-
genital disorders of glycosylation type Ia), CLPP (MIM: 614921 for con-
genital disorders of glycosylation type It), NOG (MIM: 185800 and
186500 for symphalangism 1a and multiple synostoses syndrome 1,
respectively), EIF2B2 (MIM: 603896 for leukoencephaly with vanishing
white matter syndrome) and HARS2 (MIM: 157400 for progressive exter-
nal ophtamoplegia with mitochondrial DNA (mtDNA) deletions) have
also been secondarily implicated in POI (see above) (see Table I for gene
names). Likewise, disease-associated variants in several different disease-
causing genes (TWNK, CLPP, HARS2, HSD17B4 and LARS2); in alphabet-
ical order (see Table I for gene names) are implicated in the development
of the Perrault syndrome (MIM: 233400) which associates sensorineural
hearing loss and ovarian dysfunction (Demain et al., 2017b). Finally,
CGG-expansions in the ‘pre-mutation range’ in the FMR1 gene remain a
well established cause of isolated POI, more frequent in families with
Fragile X syndrome (MIM: 300624), than in sporadic cases of POI.
Recently, dominant negative disease-associated variants in the
TUBB8 gene, causing defects in spindle assembly and leading to oocyte
maturation arrest, have been described in several families. This auto-
somal disorder was either male-transmitted or de novo and its pheno-
type was female-speciﬁc (Feng et al., 2016). Disease-associated
variants in TLE6 were linked to preimplantation embryonic lethality
(Alazami et al., 2015). Although the existence of the genuine empty
follicle syndrome (GFES) is still a matter of debate, disease-associated
variants in the LH/CG receptor gene (LHCGR) have been reported in
this disorder (Yuan et al., 2017).
There have also been advances in pharmacogenomics research
focusing on the identiﬁcation of genetic variation related to the individ-
ual response to controlled ovarian hyperstimulation (COH). While a
number of candidate genes are known, only FSH receptor (FSHR) vari-
ation (the p.Asn680Ser ‘polymorphism’) has clinical utility due to its
deﬁned predictive value (Tang et al., 2015), and this variation was also
linked to some instances of POI (Cordts et al., 2015).
The panel concludes that the increasing knowledge of the genetic back-
ground, together with rapid technological developments, could foster
improved diagnostics in FI. This means that in addition to the current rou-
tine testing of patients with POI for chromosomal aberrations and FMR1
pre-mutations, selected gene panels may soon become a useful tool
allowing identiﬁcation of additional causes of FI, and thus improve genetic
and reproductive counselling and patient stratiﬁcation. The same is true
for infertile women producing no or only nonviable oocytes or those suf-
fering from premature menopause. Eventually, oocyte donation could be
offered in a more personalised manner in FI.
Advances in PGT
PGT is deﬁned as the multidisciplinary clinical application of genetic
and ART technologies aimed at the examination of a limited number
of cells of an embryo in its preimplantation phase of development
in vitro, i.e. within the context of IVF. PGT is a complex sequential
laboratory procedure, which requires multidisciplinary collaboration of
ART specialists with laboratory geneticists experienced in the analysis
of minimal numbers of cells.
Currently, the arbitrary distinction between the two major PGT
modalities, comprising PGD and PGS, is gradually vanishing as genome-
wide SNV and CNV variation genetic laboratory testing is being carried
out simultaneously from the technical point of view by MPS. This is also
reﬂected by the proposed change of nomenclature for these laboratory
procedures within the ‘International glossary on infertility and fertility
care’ which is currently in preparation by the International Committee
for Monitoring Assisted Reproductive Technology (ICMART; Zegers-
Hochschild et al., 2017). There, PGT would become the ‘root procedural
term’ to which chromosomal aneuploidy screening/testing (PGT-A) and
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PGT monogenic disease diagnosis (PGT-M), or any other genetic testing
modality, could be annexed.
PGT-M is aimed at diagnosing a speciﬁc ‘Mendelian’ genetic disorder
in the embryo for which the prospective parents are at increased risk
(Traeger-Synodinos, 2017). PGT-M has an advantage over conven-
tional PND as it precludes the need to consider ETP in an affected
ongoing pregnancy.
PGT-A (also known in the literature as PGS, ‘PGD for aneuploidy
screening/testing/-PGD-AS’ or ‘PGD for aneuploidy—PGD-A’) is
aimed at the detection of chromosomal aneuploidy (one or more of
the 23 human chromosomes) in order to select (i.e. ‘screen’) embryos
without disease-associated chromosomal aberrations. These embryos
are expected to have the highest chance of proceeding to a healthy
live-birth. PGT-A is principally carried out to improve IVF efﬁciency
(Geraedts and Sermon, 2016). The beneﬁcial effect of PGT-A utilising
‘comprehensive chromosome screening’ technology on clinical and
sustained implantation rates, in particular in patients with normal ovar-
ian reserve, has been documented in a meta-analysis (Dahdouh et al.,
2015). However, as the studies included in the aforementioned paper
only refer to good prognosis patients, more data are needed to con-
ﬁrm the validity of PGT-A for improving the clinical outcome of PGT-
A in other patient categories and various stages of embryo biopsy
(Harper et al., 2017). It is important to note that since ‘IVF success’
has been deﬁned by different authors in many ways, it is almost impos-
sible to compare the outcomes of various studies within evidence-
based meta-analysis (Geraedts and Sermon, 2016). Better patient
stratiﬁcation prior to PGT-A would help to assess which testing strat-
egy is optimal for speciﬁc patient populations. Therefore, currently the
beneﬁcial effects of PGT-A do not have a sufﬁcient level of evidence,
as the results of standardised RCTs have not been published (Harper
et al., 2017). Since PGT-A is costly, ‘positive’ RCT outcomes also com-
monly represent a prerequisite for PGT-A reimbursement within most
European healthcare systems.
Since improved vitriﬁcation methods are currently being introduced
(Vajta et al., 2015) and a speciﬁc RCT has been carried out (Coates et al.,
2017), selection of fresh embryos for transfer by PGT is increasingly being
replaced by frozen embryo transfer. This approach allows for more time
to perform high-quality PGT and aggregate more ‘diagnostic cases’ for
simultaneous examination, which also decreases costs. Essentially, the
increased utilisation of evidence-based PGT is intertwined with advances
in embryo vitriﬁcation and reliant on high-quality expertise in embryo
micromanipulation (Geraedts and Sermon, 2016), including properly
established indicators (Wilkinson et al., 2017).
Whole-genome haplotyping approaches, e.g. karyomapping (Natesan
et al., 2014a, b; Thornhill et al., 2015), as well as MPS-based whole-gen-
ome ‘deep sequencing’ allows for concurrent haplotyping, SNV and
CNV examination, hence enabling aneuploidy assessment when speciﬁc
PGT and informatics approaches are applied (Zamani Esteki et al., 2015).
Haplotyping enables reliable PGT-M for virtually any inherited disease-
associated variants (even without the necessity of a prior work up identi-
fying the respective variants within a given family), while genome-wide
low-coverage MPS allows PGT-A, including diagnosis of partial chromo-
somal aneuploidies down to as little as 1.8 Mbp in size (Zheng et al.,
2015; Sermon et al., 2016; Vermeesch et al., 2016). Whereas most PGT-
M testing methods to date had focused on analysing a single locus or
a localized region of the genome, novel technical approaches may pro-
vide broader examination of an embryo‘s genomic variation. As a
consequence, not only the genetic variants of interest, but also genomic
variation unrelated to the original referral and request of the couple, may
be detected. This approach opens novel ethical issues to be explored
(Hens et al., 2013; Van den Veyver, 2016) and subsequently professional
guidelines ought to be developed.
PGT, like all forms of clinical genetic testing, requires strict quality
assurance and assessment. Regular participation in external quality
assessment should be considered as essential and is indeed obligatory
for genetic tests in some countries. PGT-speciﬁc schemes are readily
available for both monogenic and aneuploidy testing in Europe, and
beyond. Laboratory accreditation according to ISO15189 is still con-
sidered the most effective route to quality assurance (Harper et al.,
2010) and its uptake is increasing in Europe, and beyond. It needs to
be noted that technique-speciﬁc guidelines, such as those for diagnos-
tic MPS, are equally relevant and important for PGT and should be
observed (Matthijs et al., 2016; Marianowski et al., 2016).
Likewise, the ‘Standards and guidelines for the interpretation of
sequence variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association for
Molecular Pathology’ should be observed (Richards et al., 2015).
Moreover, Human Genome Variation Society recommendations on
sequence variant nomenclature and proper assignment of ‘disease
association’ in detected variants (hence reserving the preﬁx ‘patho-
genic’ only to a clear set of diagnostic situations denoting that a given
variant ‘causes disease when in a speciﬁc context’) (HGVS, 2017),
including relevant recommendations for the reporting of diagnostic
tests, ought to be followed in PGT (Claustres et al., 2014).
Another issue related to the clinical implementation of PGT-A is due
to the fact that embryo mosaicism challenges provision of categorical
(or ‘conclusive’) results. Although trophectoderm (TE; ‘Day 5’ or ‘Day
6’) biopsy allows for obtaining ‘aggregate’ template DNA from multiple
embryonic cells, rather than one or two cells within a blastomere (‘Day
3’) biopsy, it remains merely a general biopsy technique with its inher-
ent limitations regarding the representativeness of the sample drawn in
terms of the tissue/organ under study. These limitations are similar to
those currently discussed in the domain of cancer, where accurate diag-
nosis and/or replicable research progress also to a large extent depend
on the experience of the biopsy operator and exact position of the
biopsy within the tissue of interest (Kamps et al., 2017). Therefore, the
sample of cells obtained by embryo biopsy (at any given developmental
stage) might not be representative of the entire embryo, as high rates
of mosaicism have been also reported at the blastocyst stage (Fragouli
and Wells, 2011). In conclusion, while MPS improves analytical sensitiv-
ity and thus detection of mosaicism in a given embryo biopsy, it does
not remedy the limitation that only the cells present in the biopsy are
being analysed (Scott and Galliano, 2016).
There already are reports on successful pregnancy outcomes follow-
ing the replacement of selected mosaic aneuploidy blastocysts
(Albertini and Gleicher, 2015; Greco et al., 2015). This observation,
potentially changing the current paradigm of PGT-A, calls for follow-up
multicentric studies to this initial observation and to duly prioritise
embryos for transfer in terms of quantitative and qualitative para-
meters of embryo chromosomal mosaicism. The chance of a healthy
live-birth will vary depending both on the rate of mosaicism and on the
type of aneuploidy (which chromosome, monosomy versus trisomy,
are involved). The current challenge in this ﬁeld is thus to deﬁne ‘cut-
off’ levels, allowing to classify embryos as transferrable as ﬁrst priority
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(i.e. no mosaicism detected), transferrable as second priority (i.e.
moderate level of mosaicism with exclusion of those chromosomes
potentially related to viable pathological conditions) and non-
transferrable (i.e. excessive level of mosaicism or mosaics including
chromosomes potentially related to viable pathological conditions
(PGDIS, 2016)). Therefore, PGT-A could be considered primarily as a
‘ranking tool’ (i.e. a ‘quantitative selection strategy’), rather than a
‘screening tool’ (i.e. ‘qualitative selection strategy’), in order to discern
euploid embryos from aneuploid ones (Maxwell et al., 2016).
This important observation leads to further questions about who
should decide on the ranking or exclusion of embryos for transfer, and
about what information is provided by the genetic laboratory to the
ART clinician and IVF laboratory, and the prospective parents (Hens
et al., 2013). Comprehensive reproductive and genetic counselling
with the latter is needed in order to ensure an adequate understanding
by couples of the possibilities and limitations of the current genomics
and ART approaches related to PGT-A. Infertile couples also need to
be made transparently aware of the fact that PGT-A alone cannot
increase the live-birth rate per cycle initiated, since it represents a
ranking mechanism, not a therapy per se (Harper et al., 2017).
However, secondary outcome measures, such as mitigation of embryo
implantation failures, miscarriage rate and cost-effectiveness may be
positively affected by performing PGT-A in speciﬁc patient populations
(Geraedts and Sermon, 2016; Sermon et al., 2016; Munné and Cohen,
2017). PGT-A also allows negative selection of embryos with viable tri-
somies in selected couples with limited reproductive prospects, for
example owing to parental age. As current evidence is limited, more
research has to be carried out and data from multicentric RCTs need
to be gathered by harmonised methodologies, thereby enabling the
proposed ‘PGS 2.0’ concept (Gleicher et al. 2014; Geraedts and
Sermon, 2016; Murugappan et al., 2016; Gleicher and Orvieto, 2017).
Utilisation of advanced MPS-based technologies allowing sensitive and
speciﬁc laboratory testing procedures together with the appropriate
standardisation of IVF success reporting in accordance with the pro-
posed The International Glossary on Infertility and Fertility Care, 2017;
see above ICMART glossary (see above) could foster replicability of
RCTs in PGT-A.
Even in the absence of RCTs, PGT-A is currently practised in an
increasing number of laboratories globally. As soon as there is proven
laboratory technology which can select clearly non-viable embryos
based on their chromosome constitution, the application of PGT-A
could be considered as a part of medical practice in high-risk cases
(e.g. with advanced maternal age). By avoiding inevitable failure of
respective ART cycles by deselecting evidently non-viable chromoso-
mally abnormal embryos, PGT-A may mitigate unnecessary suffering
of patients, improve the overall efﬁciency of IVF in the couple involved
and decrease unnecessary COH-related costs.
There has been promising research progress in the utilisation of blas-
tocoele ﬂuid (BF) (Gianaroli et al., 2014; Magli et al., 2016) serving as an
alternative source of template DNA for PGT carried out by MPS
(Zhang et al., 2016b). BF reﬂects the chromosome status of the embryo
(i.e. of the inner cell mass; ICM), compared to the sampling of TE cells,
which represent only the extra-embryonal tissues. BF is sampled by
aspiration with a ﬁne needle (blastocentesis), prior to embryo vitriﬁca-
tion (see above). It has been documented that the timing of blastocoele
re-expansion in vitriﬁed-warmed cycles represents a favourable pre-
dictive factor for positive clinical pregnancy outcome: the faster the re-
expansion of the blastocoele, the higher the further developmental
potential of the blastocyst (Lin et al., 2017). Research in this area is
ongoing but when technical difﬁculties are overcome and outcomes of
PGT-A following blastocentesis could be independently validated, then
BF may become the preferred source of DNA for PGT.
Finally, utilisation of extracellular embryonic ‘matrices’, for example
drawn from spent in vitro culture media (CM), represents another
research avenue for sampling of template DNA (although likely frag-
mented) for ‘non-invasive PGT’. However, there are concerns that
CM are not produced under ‘human DNA-free’ conditions and/or
there remains a possibility that residual DNA from maternal (for
example cumulus) cells could be present (Galluzzi et al., 2015;
Hammond et al., 2017).
The future of PGT is closely related to the development of novel
genome-wide MPS strategies, but also reliant on advances in blastocyst
vitriﬁcation, together with appropriate embryo micromanipulation
expertise of a given IVF centre. The majority of relevant professional
guidelines for genetic/genomic testing within the ‘postnatal domain’ are
applicable to PGT, including rigorous adherence to quality assurance.
The panel calls for a balanced view on the current role PGT-A in
ART in terms of the overall improvement of IVF efﬁciency. Currently,
PGT-A represents a ranking mechanism, which has documented posi-
tive impact in selected patient populations regarding positive second-
ary outcome measures such as reduction of embryo implantation
failures or miscarriage rates.
The panel also calls for a standardised description of IVF success
reporting (for example related to live-birth rate) so that current
and/or future RCTs related to application of novel PGT-A
approaches could be replicated and thus stand up to the require-
ments of evidence-based medicine, hence in support of the ‘PGS 2.0
concept’.
Whole-genome approaches to PGT-A offer the potential to priori-
tize embryo transfer not only on the basis of the absence of disease-
associated (SNV/CNV) variants related to the primary genetic referral
and request of the infertile couple, but also the overall genetic consti-
tution of the embryo. However, guidelines on how to use this informa-
tion in the genetics laboratory are lacking, as are relevant ethical
considerations, and thus need to be addressed by professional soci-
eties in the near future. Hopefully, novel techniques related to utilisa-
tion of BF or spent CM could overcome invasive template DNA
sampling of the early embryo for PGT.
Non-invasive PND and prenatal
screening
Similarly to ‘procedural’ characterisation of PGT (see above), the term
NIPT should be generally reserved for the description of genetic tech-
nologies utilising the analysis of cell-free ‘foetal’DNA (cffDNA) circulating
in the maternal plasma (Lo et al., 1997). Nonetheless, due to the initial
clinical application of NIPT for the detection of selected foetal chromo-
somal aneuploidies (i.e. for chromosomes 13, 18, 21, X and Y) this term
historically coalesced with this primary screening purpose (see below).
The ‘foetal fraction’ comprises ~10% of cffDNA in the ﬁrst trimester
of pregnancy, and derives from the placenta. NIPT is equivalent to the
concept of ‘liquid biopsy’ of the placenta, with all its diagnostic limita-
tions historically gathered from the utilisation of chorionic villus biopsy
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(Tamminga et al., 2016; Van Opstal and Srebniak, 2016) as a source of
template DNA in PND. The circulating genetic material of foetal origin
can be either used for non-invasive prenatal diagnosis (NIPD) of, for
example, monogenic disorders (Drury et al., 2016; Verhoef et al.,
2016), and/or to ‘screen’ for foetal chromosomal aneuploidy by NIPT
(alternative terminology: non-invasive prenatal screening—NIPS
(Gregg et al., 2016)). The term NIPS is more appropriate since this
prenatal screening process may also involve pregnant women without
a priori genetic indication for their testing, such as in population-based
screening schemes.
Implementation of NIPS in PND clinical practice has received con-
siderable attention from professional societies which have developed
relevant guidelines (Wilson et al., 2013; ISPD, 2015; Gregg et al.,
2016). Additional reports duly assessed the global outlook and barriers
to the implementation of NIPS within the context of PND (Minear
et al., 2015; Brewer et al., 2017), including its role in ‘post-PGD’
(Bustamante-Aragones et al., 2014) pregnancies. Relevant ethical
issues have been reviewed in a joint ESHG/American Society of
Human Genetics document (Dondorp et al., 2015) and recently by the
Nufﬁeld Council of Bioethics (Nufﬁeld Council on Bioethics, 2017).
NIPS has been widely introduced in the context of prenatal screen-
ing for common chromosomal aneuploidies from as early as the 10th
week of pregnancy (Chitty and Bianchi, 2015). Low-coverage genome-
wide MPS together with advanced (often proprietary) bioinformatic
algorithms are often used to determine the number of DNA-
fragments from each targeted chromosome in order to determine the
probability of foetal chromosomal aneuploidy. Other approaches
assess copy-number by microarray or SNV analyses (Mersy et al.,
2013; Vermeesch et al., 2016). The main beneﬁt as compared with
traditional combined ﬁrst trimester antenatal screening (cFTS) (Wald
et al., 2013), which is based on maternal age, ultrasound assessment of
foetal nuchal translucency (NT) and selected biochemical biomarkers
in maternal blood, are higher detection rates and a much lower per-
centage of false-positive (FP) results (~0.1% in NIPS as compared
cFTS where it could be up to 5%). NIPS thus reduces the overall num-
ber of follow-up invasive PND procedures and potentially iatrogenic
miscarriages (Norton and Wapner, 2015; Taylor-Phillips et al., 2016;
Gil et al., 2017). Nonetheless, there is increasing evidence that NIPS
and cFTS are complementary approaches within the process of com-
plex provision of antenatal screening in low- and high-risk pregnancies.
Each approach has its inherent strengths and limitations, as reviewed
for cFTS (Wald et al., 2015) and for NIPS (Van den Veyver, 2016), that
could be pragmatically complemented within a synergistic (for
example, contingent) diagnostic strategy (Gil et al., 2016). Due to the
fact that to date NIPS is not reimbursed by most European healthcare
systems, compared to established cFTS regional- or nationwide
schemes, such a contigent approach might be cost effective for most
solidarity-based healthcare systems. For example, the UK NHS Rapid
protocol suggests NIPS in women with a deﬁned cFTS-related risk
range, and thus might assure equitable access to antenatal screening
(Hill et al., 2014; Drury et al., 2016).
There are several speciﬁc issues related to the implementation of
NIPS within broad antenatal screening strategies (Liehr et al., 2017).
The ﬁrst issue to be taken into account is related to the fact that,
unlike NIPD for monogenic disorders, NIPS is not a diagnostic test.
Tested individuals need to be aware that accuracy of NIPS is affected
by conﬁned placental mosaicism or detection of unexpected maternal
chromosomal abnormalities. Thus, NIPS carried out by whole-genome
techniques is not only a ‘liquid biopsy’ of the placenta (Amant et al.,
2015; Vermeesch et al., 2016), but also detects other circulating DNA
material, for example originating from circulating tumour cells (Bianchi
et al., 2015; Salvi et al., 2016).
The second issue is related to discussions as to how NIPS optimally
ﬁts within a comprehensive prenatal screening policy, taking into
account also its cost-effectiveness (Morris et al., 2014; Gyselaers et al.,
2015), and optimisation of its diagnostic yield (Petersen et al., 2014). A
‘contingent’ procedure, offering NIPS for intermediate risk cases after
cFTS, would be beneﬁcial in terms of costs and mitigate maternal
stress following an inconclusive cFTS result. However, both the high
sensitivity of NIPS and shorter waiting time are valuable if NIPS is
applied as a ﬁrst-line test. In this regard, studies which assessed the
clinical utility of NIPS offered through primary obstetrical care provi-
ders to a general population of pregnant women provided evidence
that NIPS has a high uptake and that patients understand its basic con-
cept and limitations. The authors concluded that NIPS could be inte-
grated into routine antenatal screening practice in primary care.
Moreover, the complementarity of prenatal ultrasound NT measure-
ments within the context of NIPS was also discussed (O’Brien et al.,
2017; Palomaki et al., 2017).
The third issue is whether NIPS should be offered for other abnor-
malities beyond common chromosomal aneuploidies, including sex
chromosome abnormalities and clinically signiﬁcant microdeletions
(for example, for the detection of the DiGeorge syndrome; MIM:
188400). However, the rarity, marked genetic and clinical heterogen-
eity of these conditions, and thus the resulting low PPV, may lead to an
undesirable increase in invasive PND procedures to account for more
FP results (Benn, 2016; Rose et al., 2016). Such a scenario could undo
much of the potential beneﬁts of introducing NIPS, hence addition of
other clinical entities into NIPS ‘panels’ needs to be carefully con-
sidered. Nonetheless, some current commercial NIPS assays do
include sex chromosome abnormalities and microdeletions, some of
which may even have a variable phenotype. In some cases these may
be of maternal origin. It is unclear whether informing apparently
healthy women about their mosaicism is of clinical utility. As testing for
milder conditions may not lead to termination, the clinical utility will
depend on whether the ﬁndings enable better treatment for the child.
On the positive side, parental awareness could enable treatment of
some conditions at birth rather than waiting for symptoms to occur to
trigger postnatal testing. On the other hand, there are also concerns
that beneﬁts may be outweighed by stigmatisation after diagnosis of
phenotypically mild sex chromosomal anomalies or microdeletions.
More research is needed to clarify this balance (Dondorp et al., 2015).
Some NIPS tests may even offer new opportunities for reproductive
health, PGT and pregnancy management (Vermeesch et al., 2016). In
summary, currently improved technology seems to ‘push’ the develop-
ment of such testing offers, rather than established clinical utility and/
or relevant patient/client perspectives.
The fourth issue is related to the quality of information and counsel-
ling with regard to all relevant aspects comprising incidental ﬁndings
(Dondorp et al., 2015). There is a concern that women are insufﬁ-
ciently made aware of the fact that NIPS is not a diagnostic test and
that eventual ETP should therefore not be based on its ﬁndings alone,
especially in low-risk populations, in which the PPV is signiﬁcantly low-
er than in a high-risk population. A ‘positive’ NIPS result should always
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be followed by an invasive PND for veriﬁcation, as in all other prenatal
screening approaches.
Among the ﬁrst applications of NIPD for monogenic disorders was
foetal sexing (Rijnders et al., 2001) in X-linked recessive disorders
where the identiﬁcation of a female foetus avoids the need for invasive
PND (Miura et al., 2011). The ﬁrst gene-speciﬁc NIPD were intro-
duced for paternally inherited autosomal dominant (AD) and AR dis-
orders where parents carry distinguishable disease-associated variants
compared to the foetus. For other recessive disorders, the challenge
still is to reliably discern between genetic information deriving from the
foetus and from the pregnant woman (Drury et al., 2016; Verhoef
et al., 2016). NIPD could also be used as a follow-up (conﬁrmatory)
procedure to PGT-M, mainly as an alternative to PND, in couples who
are reluctant to undergo invasive procedures (for example due to
repeated IVF failure or parental anxiety) which are associated with a
risk of iatrogenically-induced pregnancy loss (Bustamante-Aragones
et al., 2014).
In view of future scenarios of non-invasive whole-genome NIPS,
there is a need for debate about the overall scope of antenatal screen-
ing, also taking account of the informational privacy interests of the
future child (Donley et al., 2012; Deans et al., 2015). The possibility of
foetal therapy might also impact on the indications for NIPD/NIPS in
the near future. Should intrauterine treatment become possible for an
increasing number of genetic conditions, including for example Down
syndrome (de Wert et al., 2017), then the informed decision needs to
take into account such ‘dual goals’ of antenatal screening, be it cFTS or
NIPS, or their combination.
The panel recommends that future interdisciplinary discussions are
carried out between respective professional societies which are
responsible for the implementation of non-invasive antenatal screening
policies and their potential association with the development of appro-
priate antenatal therapies. Individuals undergoing NIPS testing should
be made aware of the fact that its positive results need to be con-
ﬁrmed by invasive PND. Moreover, tested individuals should be made
aware that NIPS using whole-genome approaches may detect ‘inciden-
tal’ ﬁndings, for example circulating tumour DNA in the mother.
Finally, technological advances foster broader clinical implementation
of NIPD as a more acceptable alternative to standard PND associated
with invasive sampling of foetal cells or tissues.
Mitochondria: from diagnosis
to treatment
Preventing transmission of mtDNA disease-
associated variants
It is now technically possible to accurately establish the mtDNA disease-
associated variant load (henceforward in legacy terminology ‘mutation
load’) in different types of samples, including embryo biopsies and amni-
otic ﬂuid, and therefore select an embryo/foetus with a mutation load
below the threshold considered as ‘pathogenic’ when performing PGT-
M and PND. Therefore, PGT-M and PND may be used to lower the
risk of a child affected by various mitochondrial disorders (Otten and
Smeets, 2015; Richardson et al., 2015). However, this ‘selective’
approach suffers from several drawbacks. One important issue is that
there remains uncertainty whether the mutation load found in the tested
sample is consistently representative of the rest of the embryo/foetus.
Also, the mutation load may change during embryonic/foetal develop-
ment, and it is difﬁcult to establish the cut-off value for selection because
of the uncertainty in correlation between the mutation load and resulting
clinical symptoms. Finally, from a clinical point of view, there may be
questions on the efﬁciency of this approach, as there is no guarantee
that a woman with a given heteroplasmic load in her somatic tissues pro-
duces oocytes with a sufﬁciently low mutation load for a successful PGT
cycle (Hellebrekers et al., 2012).
To address this issue, mitochondrial replacement therapy (MRT)
has been developed (Wolf et al., 2015; Reznichenko et al., 2016).
It consists of the transplantation of pronuclei, meiotic spindle or polar
bodies of the patient’s oocytes to the cytoplasm of enucleated donor
oocytes, which are presumed to contain ‘healthy’ mitochondria.
Pronuclear transfer was ﬁrst performed in the mouse (McGrath and
Solter, 1983), but the resulting offspring showed high levels of mito-
chondrial carryover (Wolf et al., 2015). A second approach is based
on transplanting pronuclei shortly after completion of meiosis rather
than shortly before the ﬁrst mitotic division, which results in lower
mtDNA carryover (Richardson et al., 2015; Hyslop et al., 2016).
The spindle transfer technique was pioneered in the Rhesus monkey,
where it proved to be efﬁcient and safe (Tachibana et al., 2009). The
feasibility of mtDNA replacement by spindle transfer has also been
demonstrated in the human, although some of these oocytes displayed
abnormal fertilization (Tachibana et al., 2012, 2013). The ﬁrst birth of
a child after spindle transfer was reported in a mother who carried a
mtDNA mutation causing Leigh syndrome (MIM 256000) that resulted
in four pregnancy losses and two deceased children. Although the child
born after spindle transfer had a mutation load of 5.7% and was doing
well at the time of reporting, long-term follow-up is necessary (Zhang
et al., 2017a). The ﬁrst clinical pronuclear transfer in human oocytes
with the result of a healthy birth was carried out in China. It was ini-
tially reported at the annual American Society of Reproductive
Medicine Annual Meeting in 2003, but published only 13 years later
(Zhang et al., 2016a). Polar body transfer has been successfully
achieved in the mouse (Wolf et al., 2015) and recently also in humans
(Zhang et al., 2017b). However, there are inherent technical difﬁculties
as polar bodies experience a brief lifetime owing to apoptotic pres-
sures that lead to DNA fragmentation and degradation (Wolf et al.,
2015). Overall, given the experimental nature of all these approaches,
PGT and/or PND should always be considered after MRT, as an extra
‘safety net’ testing procedure.
Ethical issues under discussion include the acceptability of modifying
the human genome (Palacios-González, 2017), the role of the mito-
chondrial donor as a contributor to the ‘parental project’ (i.e. concept
of ‘three parent families’ in the lay press) and implications for offspring
identity, the proportionality of developing MRT technology as based
on a view of the importance of genetic parenthood, and ﬁnding a bal-
ance between taking appropriate precautions and hampering innov-
ation (Nufﬁeld Council on Bioethics, 2012; Bredenoord and Hyun,
2015; Fogleman et al., 2016; Gómez-Tatay et al., 2017).
Autologous germline mitochondrial transfer
to enhance/improve embryo development
Mitochondrial supplementation methods were introduced about two
decades ago with the aim of overcoming poor oocyte quality and
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repeated IVF failure (Barritt et al., 2001). Despite the promising suc-
cess rates of these ﬁrst experimental trials, further research was largely
abandoned because of safety concerns, particularly after such proce-
dures resulted in 45,X pregnancies. Articles evidencing the existence
of adult oogonial (oocyte-generating) stem cells in mice, and possibly
in women (White et al., 2012), have re-opened the prospects of deli-
vering a source of pristine and patient-matched germline mitochondria
to boost egg health and embryonic developmental potential without
the need for young donor eggs to obtain ‘healthy cytoplasm’ (Woods
and Tilly, 2015). However, broader clinical experience with this pro-
cedure is limited and the existence and role of adult oogonial stem
cells in the human is still a matter of professional debate (Albertini and
Gleicher, 2015; Erler et al., 2017).
mtDNA copy number as a marker of embryo
viability
The mtDNA quantity in TE and blastomere biopsies has been asso-
ciated with advanced female age and chromosomal aneuploidy, and
proposed to provide an independent measure of embryonic implant-
ation potential (Diez-Juan et al., 2015; Fragouli and Wells, 2015). The
quantity of mtDNA appears signiﬁcantly higher in embryos from older
women and in aneuploid embryos, independent of the patient age.
Blastocysts that successfully implant contain lower mtDNA quantities
than those failing to implant, with a mtDNA quantity threshold above
which implantation was never observed. However, many embryos
that failed to implant also had mtDNA amounts below the said thresh-
old. A recent study was not able to conﬁrm these results, and found
no statistically signiﬁcant differences in blastocysts grouped by chromo-
somal ploidy, maternal age or implantation potential after application
of a mathematical correction factor (Victor et al., 2017).
Conversely, it has been demonstrated that mtDNA is being reduced
in the preimplantation embryo prior to its subsequent increase during
the blastocyst stage (St. John, 2016). To allow proper extrapolations
from TE biopsies, it would be necessary to study the correlation
between mtDNA content in the TE and the ICM of the blastocyst.
Finally, it may be of value to measure the mtDNA content in a Day 3
embryo growing in vitro to improve identiﬁcation of viable embryos
with a high developmental potential (Stigliani et al., 2014).
The panel concluded that application of various mitochondria-
related procedures in ART still lack a sufﬁcient level of evidence, and
that further basic and translational research is necessary in this regard.
Furthermore, relevant ethical issues need to be taken into consider-
ation prior to the applications of these technologies in clinical practice.
Epigenetic inheritance-related
issues in ART
Even though multiple deﬁnitions can be found for epigenetic inherit-
ance, the most accepted one is as follows ‘any potentially stable and
heritable change in gene expression that occurs without a change in
DNA sequence’ (Hammoud et al., 2013; Seisenberger et al., 2013).
Epigenetics involves controlling the structure of the chromatin and the
switching between an open to a closed conﬁguration, thereby affecting
transcription. Different modiﬁcations take place, such as covalent
modiﬁcation of DNA by methylation and/or post-translational modiﬁ-
cations of proteins associated with DNA, mainly the histones (Smith
et al., 2014). So far, most experimental studies in the ﬁeld of epigenetic
inheritance have been performed using mouse models (Kelsey and
Feil, 2012). This implies that application of their outcomes to humans
needs to be further substantiated.
Major epigenetic changes responsible for erasure and renewed
establishment of the human epigenome occur during gametogenesis
and early embryo development. These complex molecular processes
include post-fertilization reprogramming to generate a totipotent zyg-
ote and are followed by germline reprogramming to generate gametes
(Smallwood and Kelsey, 2012). These processes together with envir-
onmental inﬂuences on the formation of human epigenome, especially
during early development, are well documented (Fleming et al., 2004;
Feil and Fraga, 2012). Consequently, there is a possibility that some
ART procedures may inadvertently alter the gamete- and/or embry-
onal epigenome and potentially generate adverse medical conse-
quences in the offspring.
The epigenetic mechanisms in gametes remain more or less a ‘black
box’ at present, especially regarding oogenesis. In mice, it has been
shown that sperm DNA can be methylated and hydroxymethylated,
but the exact role of such methylation processes is unclear. It is
believed that methylation could both have a global impact on DNA
stabilization and a speciﬁc purpose, i.e. to silence (imprint) speciﬁc
genes. It has also been shown that some speciﬁc genomic loci will keep
their histones during meiosis, instead of exchanging them for prota-
mines, and that this molecular mechanism is correlated with hypo-
methylation. It is hypothesized that the genes escaping protamination
are the ones that need to be expressed very early during embryonic
development (Hammoud et al., 2009). After fertilization, paternal
DNA is actively demethylated, but some loci remain methylated
(mainly in the case of imprinted genes). Thus far, the role of sperm
DNA methylation in future embryonic development is not well under-
stood (Krausz et al., 2012).
The level of DNA methylation in the oocyte is half of that in sperm-
atozoa. DNA methylation in the oocyte does not play a role in the regu-
lation of gene expression of the oocyte itself, but is important for
embryonic development (Clarke and Vieux, 2015). Interestingly, regions
that are methylated in the oocyte are more likely to be also methylated
in the embryo (Smallwood et al., 2011). These complex processes might
be regulated by incomplete demethylation during the post-fertilization
reprogramming of the maternal allele or another kind of memory mech-
anism and present a potential way of epigenetic intergenerational inher-
itance of environmentally induced (e.g. by COH and/or CM) alterations
in DNAmethylation patterns of the oocyte (Marianowski et al., 2016).
Another function of DNA methylation in the germline is to control
the expression of transposable elements (TPE). These are ancestral
traces of retroviruses, representing approximately one-half of the
human genome. TPE are reactivated during primordial germ cell form-
ation and early development, and are tightly controlled not to jump
‘anywhere’ in the genome. The pathway(s) controlling the expression
and transposition of TPE are not fully understood, thus far. However,
in the mouse, potentially pathogenic alterations of proteins involved in
their control can cause MI, mainly by a meiotic blockage at the pachy-
tene stage (Gifford et al., 2013; Zamudio et al., 2015). Recently, there
is also growing evidence on the implication of TPE in various human
diseases (Hancks and Kazazian, 2016).
Animal studies have shown that ART procedures may be associated
with multiple alterations in gene expression and DNA methylation,
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mainly of imprinted genes (Sunde et al., 2016). However, the potential
relationship with phenotypic outcomes (if any) remains largely
unknown. Also in human studies, epigenetic alterations associated
with ART have been reported in embryos and placental tissue or
umbilical cord blood (van Montfoort et al., 2012). However, these
alternations have not yet been unambiguously associated with any clin-
ically relevant outcomes, thus far. Future studies should focus on the
normal epigenetic regulation in human gametes and embryos, the nat-
ural inter-individual variation in, for example, DNA methylation, the
consequences of slight alterations in DNA methylation and phenotyp-
ical (long-term) consequences of epimutations (Bunkar et al., 2016).
Recently it was suggested that there is inter-individual variation in sus-
ceptibility to environmentally mediated epigenetic alterations in humans
(Ghosh et al., 2016). Furthermore, the environmentally induced epimuta-
tions occur possibly on a stochastic basis (de Waal et al., 2014) making
‘one-to-one’ associations between an environmental clue and epigenetic
alterations at a speciﬁc gene or set of genes less informative. This obser-
vation might also explain inconsistencies found between various studies.
ART-induced epigenetic alterations, if they exist, might thus occur at ran-
dom places in the genome, in only a subset of vulnerable subjects, prob-
ably leading to a wide range of adverse phenotypic consequences, which
would complicate research on the potential epigenetic effects of ART
(de Waal et al., 2014). Finally, it needs to be noted that these follow-up
studies are also hampered by common parental unwillingness to disclose
previous IVF-treatments, including data security concerns regarding rele-
vant patient registries.
The panel concluded that more research is needed on the potential
impact of speciﬁc ART procedures on the epigenome and its conse-
quences for the offspring, including possible epigenetic inheritance
pathways. In addition, standardisation of follow-up methodologies and
post-IVF patient registries could overcome complex biological issues
and foster replicability of initial observations of adverse epigenetic
inheritance-related phenomena in children/adults conceived by IVF.
Furthermore, relevant social and ethical issues related to this issue
need to be explored.
Germline genome editing
Genome editing using tools allowing for exact modiﬁcation, such as
zinc-ﬁnger nucleases and TALENs (transcription activator-like effector
nucleases), have been available for many years and have been widely
used in research (Pennisi, 2013). However, with the recent introduc-
tion of the CRISPR/Cas9 (clustered regularly interspaced short palin-
dromic repeats/Cas9 nuclease) system, genome editing has become
much simpler, cheaper and more efﬁcient, opening the road to som-
atic gene therapy and eventually also GGE (Vassena et al., 2016).
GGE can be performed in different germ cell types, such as sperm-
atogonial stem cells, in vitro matured oocytes, stem-cell derived
gametes differentiated in vitro from pluripotent stem cell lines obtained
after somatic cell nuclear transfer or induced pluripotent stem cells,
and even in the early embryo (Liang et al., 2015; Kang et al., 2016).
GGE at the embryo level has important technical drawbacks, such as
incomplete editing leading to mosaic embryos and off-target effects
(induced disease-associated variants at sites other than the intended on-
target site) that need to be solved before considering possible clinical
applications of the technique. As newer, more accurate, efﬁcient, and
therefore safer GGE systems are being developed, it is to be expected
that these technical limitations could be overcome (Ishii, 2017) as was
recently documented in the case of hypertrophic cardiomyopathy (Ma et
al., 2017).
Nevertheless, the number of clinical indications that could be envi-
saged for GGE remediation is limited, thus far, since PGT-M offers an
alternative for couples at risk for a genetic disease in their offspring.
The potential use of GGE could be envisioned in very high-risk cou-
ples, for example if one partner is homozygous for an AD disease, or
when both partners suffer from the same AR disorder. Less ‘stringent’
indications could be in cases where the number of embryos expected
to be obtained after PGT-M is small, for example in case of advanced
maternal age, or couples at high risk for transmitting more than one
genetic disease, or when HLA-matching embryos considered for cur-
ing a sibling affected by a severe monogenic disease. Other medical
ﬁelds also started to discuss the potential implications of GGE (Strong
and Musunuru, 2016). Recently, the American Society of Human
Genetics published their position statement on human GGE (Ormond
et al. 2017) and ESHG and ESHRE are also jointly developing recom-
mendations speciﬁc to this topic (de Wert et al. 2017 – ‘Responsible
innovation in human germ-line genome editing’; personal communication).
Furthermore, there is an ongoing debate on the ethical (i.e. the ‘slippery
slope’ argument) and social implications of GGE, and eventually current
restrictions on GGE may require a renewed debate (Evitt et al., 2015;
Hildt, 2016; Lunshof, 2016; Nufﬁeld Council on Bioethics, 2016). Finally, a
transparent and broad collaboration is necessary in order to move the ﬁeld
of GGE responsibly forward (Sherkow, 2016;Walton, 2016).
The panel concluded, that although research in the ﬁeld of GGE is
rapidly developing, its potential medical applications within the context
of ART and genetic medicine require further basic and translational
research. Consensus guidelines need to be developed by respective
professional societies, which will take into account any potentially
adverse individual-, population genetic-, ethical- and societal implica-
tions of this novel medical technology.
Conclusion
The intersection of ART and genomics is a fast growing scientiﬁc ﬁeld,
both from the basic and translational research points of view. A
selected portfolio of emerging topics was included in the agenda for
the third panel meeting, mainly covering issues which have the highest
potential of entering, or that are already part of, current clinical prac-
tice. As molecular genetic techniques are improved, complete charac-
terisation of the entire human genome variation of an embryo might
become a reality. Together with the emergence of therapeutic possi-
bilities comprising, for example, mitochondrial transfer and GGE, pro-
fessional and ethical discussions around these developments need to
be undertaken and international recommendations drawn up in order
to determine how such novel technologies ought to be implemented
in ART practice in a responsible and evidence-based manner, and
accordingly regulated. The panel looks forward to the fourth meeting
to discuss these ongoing developments at a European level in the near
future.
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Appendix
AD – autosomal dominant
AR – autosomal recessive
ART – assisted reproductive technology
CNV – copy number variants
CRISPR – Clustered regularly interspaced short palindromic repeats
DTC – direct to consumer (genetic testing)
ECS – expanded carrier screening
ESHG – European Society of Human Genetics
ESHRE – European Society of Human Reproduction and Embryology
ETP – elective termination of pregnancy
FI – female infertility
GGE – germline genome editing
ICMART – International Committee for Monitoring Assisted Reproductive
Technology
IVF – in vitro fertilisation
MI –male infertility
MIM –Mendelian inheritance in man (number)
MPS –massive parallel sequencing
mtDNA –mitochondrial DNA
NIPD – non-invasive prenatal diagnosis
NIPT – non-invasive prenatal testing
NIPS – non-invasive prenatal screening
PCOS – polycystic ovary syndrome
PGD – preimplantation genetic diagnosis
PGS – preimplantation genetic screening
PGT – preimplantation genetic testing
PGT – A – preimplantation genetic testing–aneuploidy
PGT –M – preimplantation genetic testing–Mendelian disorders
PND – prenatal diagnosis
PPV – positive predictive values
SNV – single nucleotide variants
SV – structural variants
WHO –World Health Organisation
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